A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial

Japanese Phase III study (n=74) found edoxaban non-inferior to warfarin in terms of ratio of pulmonary vascular resistance (PVR, Wood Units) at week 48 to PVR at baseline (ratio of geometric means for edoxaban vs. warfarin: 0.92; 95% CI 0.82 to 1.03; p <0.001 for noninferiority).

SPS commentary:

The authors note that edoxaban was shown to be non-inferior to warfarin for preventing worsening of pulmonary haemodynamics. In addition, there were no clinical worsening events and no symptomatic venous thromboembolism in either group. Rates of clinically relevant bleeding were very low, and similar for both groups.

Circulation